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ate for patient reporting in their current form, due to mixing of symptom attributes 
within items and technical jargon. The committee determined that measured attributes 
for each symptom should include frequency, severity, and activity interference. Ques-
tions and response options were standardized, along with plain language terms for 
each symptom. a web-based platform was developed for administering the new PRO-
CTCAE items. CONCLUSIONS: In response to a charge from the NCI, the PRO-
CTCAE, a patient version of the CTCAE system, has been developed. The prototype 
is undergoing testing to assess validity, usability, and logistical feasibility in a variety 
of cancer care settings. The PRO-CTCAE system has the potential to enhance adverse 
event reporting by integrating patient experiences and can foster consistency of data 
collection methods across studies.
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OBJECTIVES: Diagnosis and treatment of cancer entail a considerable amount of 
distress which in a large percentage of patients would require psychooncological treat-
ment (POT). There is though a lack of precise and economic measures for assessing 
the need for POT. Its detection in clinical routine often depends on procedural and 
personnel conditions. The aim of the study was the development and implementation 
of a patient-reported outcome tool for the screening of distress. a further aim is the 
construction of a computer-adpative testing (CAT) version. METHODS: 115 breast 
cancer outpatients attending the Department of Gynaecology at Innsbruck Medical 
University were consecutively included in a pilot study. Logistic regression analysis 
and ROC analyses identiﬁ ed the most predictive items from a set of questionnaires 
(EORTC-QLQ-C30, HADS, and Hornheide Screening Instrument) and other addi-
tional questions. The development of the CAT screening tool comprises generating an 
item bank, developing the CAT-algorithm and applying and implementing the CAT 
in clinical practice. RESULTS: Data from 105 breast cancer patients (mean age 58.8, 
SD 12.3) were analyzed. The EORTC QLQ-C30 scales Emotional Functioning and 
Role Functioning as well as the yes–no question after psychiatric/psychological/psy-
chotherapeutic treatment at any point in lifetime showed high predictive power with 
regard to need for POT (AUC = 0.88; CI 95% 0.82–0.95). The generation of the item 
bank resulted in 52 prelinimary items which will be subjected to further analyses. 
CONCLUSIONS: The implementation of precise and effective measures for POT 
needs is essential for providing comprehensive and high-quality cancer care. CAT 
methodology contributes to the reduction of patient burden and assessment duration, 
and increases efﬁ ciency as well as measurement precision.
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OBJECTIVES: Computer-adaptive testing (CAT) is an advanced method for measur-
ing patient-reported outcomes. With help of an algorithm, CAT selects the items most 
relevant for an individual patient from an item bank. Our study aim was the develop-
ment of a CAT version of the EORTC QLQ-C30 Fatigue scale, its implementation in 
a software package, and its use in daily clinical routine. METHODS: Our project is 
part of a large project on CAT development conducted by the EORTC Quality of Life 
Group. To set up an initial English fatigue item list, an extensive literature research 
was performed. These items were reﬁ ned through multistage expert reviews, translated 
to German, Danish, Spanish, French, and Dutch, and ﬁ lled in by a pilot patient sample 
to collect feedback. In a next step, a large patient sample is recruited for all language 
versions to gain data for development of the item bank and the CAT algorithm. 
RESULTS: Literature research resulted in 588 fatigue items, from which 44 were 
selected after comprehensive expert reviews. Based on feedback from 52 oncological 
patients, wording and translation of several items were revised. Data have been col-
lected from about 1200 patients. Preliminary results of the CAT-analysis will be 
presented. CONCLUSIONS: By generating individually tailored item sets, CAT 
reduces patient burden and assessment duration, and increases measurement precision. 
In addition, electronic data capture increases data quality and reduces the amount of 
human resources required for data collection.
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OBJECTIVES: To compare the economic and patient-reported outcomes between 
outpatient home-based and inpatient hospital-based chemotherapy in advanced 
colorectal cancer patients. METHODS: A total of 80 patients from Severance Hospital 
in Seoul, Korea, who had stage III colorectal cancer and underwent home-based (n = 
40) or hospital-based chemotherapy (n = 40) with a FOLFOX regimen between 
January 2007 and April 2008 were enrolled. Patient satisfaction data were collected 
by a self-administered questionnaire survey. Based on hospital charge records, average 
cost (in 2008 Korean won) per chemotherapy session was estimated and compared 
between home- and hospital-based chemotherapy from a societal perspective. 
RESULTS: Patients receiving chemotherapy at home showed higher satisfaction with 
their treatment (mean satisfaction score: 3.58 ± 0.15, 5-point Likert-type scale, with 
a higher score indicating higher satisfaction) than did those treated at the hospital 
(3.23 ± 0.21; P < 0.01). After adjusting for differences in baseline characteristics 
between the two groups using multivariate analysis, those receiving home-based che-
motherapy still showed signiﬁ cantly higher satisfaction than those undergoing hospi-
tal-based therapy (β = 0.271, P < 0.001). Additionally, home-based therapy reduced 
the cost per chemotherapy session by 16.6%, compared with hospital-based treatment 
(1,694,216 vs. 2,030,383 Korean won [KW], 1200 KW ≈ 1 US dollar). The largest 
cost reduction was attributable to medical costs (−201,122 KW), followed by care-
giver’s opportunity costs (−135,000 KW). CONCLUSIONS: Higher satisfaction and 
lower economic cost for home-based chemotherapy suggests that home-based chemo-
therapy could be a popular and cost-effective treatment option for colorectal cancer 
patients who are eligible for home-based chemotherapy.
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OBJECTIVES: Patients’ own assessment of the impact of anticancer therapy has been 
considered important from a patient, physician, payor, and regulatory perspective. 
Approximately 12% of all oncology clinical trials list at least one patient-reported 
outcome (PRO) measure; 50% of these are phase II trials. Use and publication of PROs 
results were systematically reviewed for breast, colorectal, ovarian, and non-small cell 
lung cancer (NSCLC). METHODS: Citeline’s TrialTrove database was searched for 
oncology trials that included PROs and were planned, ongoing or completed as of 
October 2009. Speciﬁ c trial factors examined include phase, disease type, location, 
sponsorship, type of PRO instrument(s), and publication of PRO endpoint results. 
RESULTS: Of the 5483 phase II trials retrieved for breast, colorectal, ovarian, and 
NSCLC, 9% listed PROs. PRO measures were more frequently included in NSCLC 
(13%) and ovarian cancer (10%) than in breast (7%) or colorectal (8%) cancer phase 
II trials. Fifty-two percent of these trials were sponsored by industry, with 25% and 
19% being sponsored by academic and cooperative groups, respectively. One-third of 
the trials were conducted in the United States only. PROs were most frequently measured 
with the EORTC and FACT series of questionnaires. Phase II PRO results were pub-
lished 24%, 36% and 39% of the time for breast, ovarian, and NSCLC, respectively, 
and only 18% of the time for colorectal cancer. This compares with an overall publica-
tion frequency for PRO trials (any end points) of 58% to 67% which was highest in 
NSCLC. PRO results were published more frequently for trials conducted in Asia or 
Europe. However, trial sponsorship did not impact publication frequency. CONCLU-
SIONS: PROs are infrequently assessed in phase II cancer trials. PRO measures were 
most frequently included in NSCLC trials and sponsored by industry. PRO results were 
published less frequently than other end points in these trials. Publication frequency 
differed by tumor type and trial location.
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OBJECTIVES: The aim of this study was to determine the smallest changes in health-
related quality-of-life (HRQOL) scores in the European Organization for Research 
and Treatment of Cancer quality of life questionnaire (EORTC QLQ-C30) and the 
EORTC Brain Cancer Module (QLQ-BN20), which could be considered as clinically 
meaningful in brain cancer patients. METHODS: World Health Organization (WHO) 
performance status (PS) and the Mini Mental State Examination (MMSE) were used 
as clinical anchors appropriate to related subscales to determine minimal clinically 
important differences (MCID) in HRQOL change scores (range 0–100) in the EORTC 
QLQ-C30 and QLQ-BN20. a threshold of 0.2SD (small effect) was used to exclude 
anchor-based MCID estimates considered too small to inform interpretation. 
RESULTS: Based on WHO PS, our ﬁ ndings support the following integer estimates 
of the MCID for improvement and deterioration, respectively: physical functioning 
(6, 9), role functioning (14, 12), cognitive functioning (8, 8), global health status (7, 
4*), fatigue (12, 9), and motor dysfunction (4*, 5). Anchoring with MMSE, cognitive 
